Home
Live Updates
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update : vimarsana.com
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED)...
Related Keywords
United States ,
American ,
Carl Spana ,
Palatin Technologies Inc ,
Cosette Pharmaceuticals ,
Prnewswire Palatin Technologies Inc ,
Vyleesi To Cosette Pharmaceuticals ,
Metabolic Program Obesity ,
Asset Sale To Cosette Pharmaceuticals ,
Sexual Health Program Male Dysfunction ,
Bremelanotide Co ,
Securities Exchange ,
Melanocortin Receptor ,
Dry Eye Disease ,
Topline Data Expected ,
Ulcerative Colitis ,
Interim Analysis Expected ,
Calendar Year ,
Topline Results Expected ,
Study Targeted ,
Sexual Dysfunction ,
Bremelanotide Co Formulated ,
Asset Sale ,
Gross Proceeds ,
Second Quarter Ended December ,
Health Program ,
Female Sexual Dysfunction ,
Direct Offering ,
Common Warrants ,
Registered Direct Offering ,
Eastern Time ,
Melanocortin Receptor Agonists ,
Palatin Technologies ,
Securities Act ,
Securities Exchange Act ,
Private Securities Litigation Reform Act ,
Months Ended December ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.